Peer-reviewed veterinary case report
MRI use to check ultrasound tumor treatment in dogs with bone cancer
By Vickers, Elliana R et al.·Published in Ultrasound in medicine & biology·2026·Virginia Polytechnic Institute and State University, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: MRI for the Assessment of Histotripsy Ablation in a Canine Osteosarcoma Comparative Oncology Model.
- Species:
- dog
Plain-English summary
A group of eight dogs with osteosarcoma (a type of bone cancer) underwent a new treatment called histotripsy, which uses focused ultrasound to destroy tumor tissue. Before and after the treatment, veterinarians used MRI scans to see how well the treatment worked. The scans showed that the targeted tumor areas had significantly reduced signals, indicating successful ablation of the tumor. After the treatment, the dogs also had standard surgery to remove the remaining tumor, and the results confirmed that the histotripsy effectively targeted the cancerous tissue. This approach may offer a promising non-invasive option for treating bone tumors in dogs and potentially in humans.
People also search for: dog osteosarcoma treatment · histotripsy for dog cancer · MRI for dog tumor assessment
Abstract
OBJECTIVE: To explore the use of MRI for evaluation of mechanical focused ultrasound (histotripsy) ablation in spontaneous canine osteosarcoma (OS) as a comparative oncology model of human OS. METHODS: A retrospective analysis was conducted on MR images from a veterinary clinical trial, with the purpose of using canine OS as a preclinical model in which to study human OS. Eight dogs received histotripsy treatment to a portion of their tumor, with pre- and post-treatment MRI (pre- and post-contrast T1- and T2-weighted). Dogs then received standard-of-care surgical resection. Qualitative assessments included characterization of ablation on MRI, gross anatomy, and histopathology. Quantitative assessments included measurements of ablation on MRI and gross anatomy, as well as scoring tumor bone production in untreated tumor on MRI and histopathology to compare tumor composition assessments across modalities. RESULTS: Contrast-enhanced sequences with and without subtraction reliably visualized histotripsy ablation. For all dogs, the ablation zone was visible as a nonenhancing, hypointense region. There was a significant decrease in normalized mean signal intensity of the targeted tumor region from pre- to post-histotripsy. No significant differences were found between MRI and gross measurements of ablation dimensions and volume. Histopathology confirmed ablation in the targeted regions as identified grossly and on MRI, and tumor bone composition assessments on MRI and histopathology had a significant positive correlation. CONCLUSIONS: MRI is a valuable tool for the assessment of histotripsy ablation in OS and builds upon the potential of histotripsy as a non-invasive therapy for bone tumors in dogs and humans.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/41109828/